Exact Sciences Unveils Blood Test Showing Superior Early Detection of Liver Cancer in Landmark Study

Reuters

Nov 07, 2025

Exact Sciences Unveils Blood Test Showing Superior Early Detection of Liver Cancer in Landmark Study

Exact Sciences Corporation has announced pivotal clinical validation results from the ALTUS study (NCT: 05064553), evaluating the company's Oncoguard® Liver blood test for the early detection of hepatocellular carcinoma $(HCC)$, the most common form of liver cancer. The prospective, head-to-head trial demonstrated that the Oncoguard Liver test offers superior early-stage and overall sensitivity compared to the current standard of care. The test combines DNA methylation and protein markers to detect molecular signatures associated with liver cancer. According to Exact Sciences, the ALTUS study is the largest prospective, real-world trial of a blood test for liver cancer surveillance, and the results will be presented as late-breaking data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® on November 11, 2025. The company intends to submit the data for publication in a peer-reviewed journal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251107000844) on November 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581882988"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581882988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581882988?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581882988","market":"us","top_or_hot":-1,"title":"Exact Sciences Unveils Blood Test Showing Superior Early Detection of Liver Cancer in Landmark Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exact Sciences Unveils Blood Test Showing Superior Early Detection of Liver Cancer in Landmark Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exact Sciences Corporation has announced pivotal clinical validation results from the ALTUS study (NCT: 05064553), evaluating the company's Oncoguard® Liver blood test for the early detection of hepatocellular carcinoma <a href=\"https://laohu8.com/S/HCC\">$(HCC)$</a>, the most common form of liver cancer. The prospective, head-to-head trial demonstrated that the Oncoguard Liver test offers superior early-stage and overall sensitivity compared to the current standard of care. The test combines DNA methylation and protein markers to detect molecular signatures associated with liver cancer. According to Exact Sciences, the ALTUS study is the largest prospective, real-world trial of a blood test for liver cancer surveillance, and the results will be presented as late-breaking data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® on November 11, 2025. The company intends to submit the data for publication in a peer-reviewed journal.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251107000844) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exact Sciences Unveils Blood Test Showing Superior Early Detection of Liver Cancer in Landmark Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExact Sciences Unveils Blood Test Showing Superior Early Detection of Liver Cancer in Landmark Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exact Sciences Unveils Blood Test Showing Superior Early Detection of Liver Cancer in Landmark Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exact Sciences Corporation has announced pivotal clinical validation results from the ALTUS study (NCT: 05064553), evaluating the company's Oncoguard® Liver blood test for the early detection of hepatocellular carcinoma <a href=\"https://laohu8.com/S/HCC\">$(HCC)$</a>, the most common form of liver cancer. The prospective, head-to-head trial demonstrated that the Oncoguard Liver test offers superior early-stage and overall sensitivity compared to the current standard of care. The test combines DNA methylation and protein markers to detect molecular signatures associated with liver cancer. According to Exact Sciences, the ALTUS study is the largest prospective, real-world trial of a blood test for liver cancer surveillance, and the results will be presented as late-breaking data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® on November 11, 2025. The company intends to submit the data for publication in a peer-reviewed journal.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251107000844) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXAS","symbol_name":"精密科学","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL1qGGgd:1","article_id":"2581882988","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581882988","pubTimestamp":1762520505,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Exact Sciences Corporation has announced pivotal clinical validation results from the ALTUS study , evaluating the company's Oncoguard Liver blood test for the early detection of hepatocellular carcinoma , the most common form of liver cancer. The prospective, head-to-head trial demonstrated that the Oncoguard Liver test offers superior early-stage and overall sensitivity compared to the current standard of care. The test combines DNA methylation and protein markers to detect molecular signatures associated with liver cancer. According to Exact Sciences, the ALTUS study is the largest prospective, real-world trial of a blood test for liver cancer surveillance, and the results will be presented as late-breaking data at the American Association for the Study of Liver Diseases  The Liver Meeting on November 11, 2025. The company intends to submit the data for publication in a peer-reviewed journal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXAS":"精密科学","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4139":"生物科技","BK4548":"巴美列捷福持仓","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD"},"translate_title":"Exact Sciences推出血液测试，在里程碑式的研究中显示出卓越的肝癌早期检测能力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":0.9},"content_text":"Exact Sciences Unveils Blood Test Showing Superior Early Detection of Liver Cancer in Landmark Study\n    \n\n        Exact Sciences Corporation has announced pivotal clinical validation results from the ALTUS study (NCT: 05064553), evaluating the company's Oncoguard® Liver blood test for the early detection of hepatocellular carcinoma $(HCC)$, the most common form of liver cancer. The prospective, head-to-head trial demonstrated that the Oncoguard Liver test offers superior early-stage and overall sensitivity compared to the current standard of care. The test combines DNA methylation and protein markers to detect molecular signatures associated with liver cancer. According to Exact Sciences, the ALTUS study is the largest prospective, real-world trial of a blood test for liver cancer surveillance, and the results will be presented as late-breaking data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® on November 11, 2025. The company intends to submit the data for publication in a peer-reviewed journal.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251107000844) on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}